🔴 Corcept Therapeutics is trading 7% down in pre-market after investors focused on unchanged 2026 revenue guidance

Corcept Therapeutics is trading at $76.23 (-6.96%) as investors reacted to unchanged 2026 revenue guidance despite earnings and revenue beating expectations.

• Third-quarter revenue was $340.5 million, up 64% year over year, and net income was $126.8 million.
• The company reiterated 2026 revenue guidance of $1.1–$1.2 billion.
• The decline continued into pre-market trading. Major U.S. indices were higher, so broad-market weakness does not appear to explain the move.